PP 3EGFR-kinase inhibitor. Also Src kinase negative control CAS# 5334-30-5 |
- PP 1
Catalog No.:BCC3630
CAS No.:172889-26-8
Quality Control & MSDS
Number of papers citing our products
Chemical structure
3D structure
| Cas No. | 5334-30-5 | SDF | Download SDF |
| PubChem ID | 4879 | Appearance | Powder |
| Formula | C11H9N5 | M.Wt | 211.22 |
| Type of Compound | N/A | Storage | Desiccate at -20°C |
| Solubility | Soluble to 100 mM in DMSO and to 25 mM in ethanol | ||
| Chemical Name | 1-phenylpyrazolo[3,4-d]pyrimidin-4-amine | ||
| SMILES | C1=CC=C(C=C1)N2C3=C(C=N2)C(=NC=N3)N | ||
| Standard InChIKey | KKDPIZPUTYIBFX-UHFFFAOYSA-N | ||
| Standard InChI | InChI=1S/C11H9N5/c12-10-9-6-15-16(11(9)14-7-13-10)8-4-2-1-3-5-8/h1-7H,(H2,12,13,14) | ||
| General tips | For obtaining a higher solubility , please warm the tube at 37 ℃ and shake it in the ultrasonic bath for a while.Stock solution can be stored below -20℃ for several months. We recommend that you prepare and use the solution on the same day. However, if the test schedule requires, the stock solutions can be prepared in advance, and the stock solution must be sealed and stored below -20℃. In general, the stock solution can be kept for several months. Before use, we recommend that you leave the vial at room temperature for at least an hour before opening it. |
||
| About Packaging | 1. The packaging of the product may be reversed during transportation, cause the high purity compounds to adhere to the neck or cap of the vial.Take the vail out of its packaging and shake gently until the compounds fall to the bottom of the vial. 2. For liquid products, please centrifuge at 500xg to gather the liquid to the bottom of the vial. 3. Try to avoid loss or contamination during the experiment. |
||
| Shipping Condition | Packaging according to customer requirements(5mg, 10mg, 20mg and more). Ship via FedEx, DHL, UPS, EMS or other couriers with RT, or blue ice upon request. | ||
| Description | Negative control for the Src kinase inhibitor PP 2. Inhibits EGFR kinase (IC50 = 2.7 μM). |
PP 3 Dilution Calculator
PP 3 Molarity Calculator
| 1 mg | 5 mg | 10 mg | 20 mg | 25 mg | |
| 1 mM | 4.7344 mL | 23.672 mL | 47.344 mL | 94.688 mL | 118.36 mL |
| 5 mM | 0.9469 mL | 4.7344 mL | 9.4688 mL | 18.9376 mL | 23.672 mL |
| 10 mM | 0.4734 mL | 2.3672 mL | 4.7344 mL | 9.4688 mL | 11.836 mL |
| 50 mM | 0.0947 mL | 0.4734 mL | 0.9469 mL | 1.8938 mL | 2.3672 mL |
| 100 mM | 0.0473 mL | 0.2367 mL | 0.4734 mL | 0.9469 mL | 1.1836 mL |
| * Note: If you are in the process of experiment, it's necessary to make the dilution ratios of the samples. The dilution data above is only for reference. Normally, it's can get a better solubility within lower of Concentrations. | |||||
Calcutta University
University of Minnesota
University of Maryland School of Medicine
University of Illinois at Chicago
The Ohio State University
University of Zurich
Harvard University
Colorado State University
Auburn University
Yale University
Worcester Polytechnic Institute
Washington State University
Stanford University
University of Leipzig
Universidade da Beira Interior
The Institute of Cancer Research
Heidelberg University
University of Amsterdam
University of Auckland
TsingHua University
The University of Michigan
Miami University
DRURY University
Jilin University
Fudan University
Wuhan University
Sun Yat-sen University
Universite de Paris
Deemed University
Auckland University
The University of Tokyo
Korea University
- Isogosferol
Catalog No.:BCN5704
CAS No.:53319-52-1
- Benzyl carbazate
Catalog No.:BCC8872
CAS No.:5331-43-1
- L-NMMA acetate
Catalog No.:BCC6788
CAS No.:53308-83-1
- 1,2,4-Benzenetriol
Catalog No.:BCC8409
CAS No.:533-73-3
- Sesamol
Catalog No.:BCN2594
CAS No.:533-31-3
- Tigloidine
Catalog No.:BCN1945
CAS No.:533-08-4
- Fmoc-Cys(Bzl)-OH
Catalog No.:BCC3475
CAS No.:53298-33-2
- CV 1808
Catalog No.:BCC7163
CAS No.:53296-10-9
- [Ala11,D-Leu15]-Orexin B
Catalog No.:BCC5877
CAS No.:532932-99-3
- Boc-Tyr(Me)-OH
Catalog No.:BCC3268
CAS No.:53267-93-9
- H-Sar-NH2.HCl
Catalog No.:BCC3333
CAS No.:5325-64-4
- 2''-O-Galloylhyperin
Catalog No.:BCN1218
CAS No.:53209-27-1
- Z-Leu-OH.DCHA
Catalog No.:BCC2765
CAS No.:53363-87-4
- Boc-N-Me-Leu-OH
Catalog No.:BCC2616
CAS No.:53363-89-6
- trans,trans-Bis(4-fluorobenzal)acetone
Catalog No.:BCC9180
CAS No.:53369-00-9
- 1,3,5-Trihydroxy-4-prenylxanthone
Catalog No.:BCN5705
CAS No.:53377-61-0
- Isovitexin 2'-O-arabinoside
Catalog No.:BCN7826
CAS No.:53382-71-1
- Erteberel (LY500307)
Catalog No.:BCC4491
CAS No.:533884-09-2
- 2-Aminodiphenylamine
Catalog No.:BCC8548
CAS No.:534-85-0
- D-Leu-ol
Catalog No.:BCC2583
CAS No.:53448-09-2
- 2-Aminonicotinic acid
Catalog No.:BCC8552
CAS No.:5345-47-1
- Vaccarin
Catalog No.:BCN2277
CAS No.:53452-16-7
- 16-Kaurene-2,6,15-triol
Catalog No.:BCN5706
CAS No.:53452-32-7
- Creticoside C
Catalog No.:BCN5707
CAS No.:53452-34-9
Use of a pharmacophore model for the design of EGF-R tyrosine kinase inhibitors: 4-(phenylamino)pyrazolo[3,4-d]pyrimidines.[Pubmed:9357527]
J Med Chem. 1997 Oct 24;40(22):3601-16.
In the course of the random screening of a pool of CIBA chemicals, the two pyrazolopyrimidines 1 and 2 have been identified as fairly potent inhibitors of the EGF-R tyrosine kinase. Using a pharmacophore model for ATP-competitive inhibitors interacting with the active site of the EGF-R protein tyrosine kinase (PTK), the class of the pyrazolo[3,4-d]pyrimidines was then optimized in an interactive process leading to a series of 4-(phenylamino)-1H-pyrazolo[3,4-d]-pyrimidines as highly potent inhibitors of the EGF-R tyrosine kinase. The most potent compounds 13, 14, 15, 17, 19, 22, 26, 28, and 30 of this series inhibited the EGF-R PTK with IC50 values below 10 nM. High selectivity toward a panel of nonreceptor tyrosine kinases (c-Src, v-Abl and serine/threonine kinases (PKC alpha, CDK1) was observed. In cells, EGF-stimulated cellular tyrosine phosphorylation was inhibited by compounds 13, 15, 19, 22, and 23 at IC50 values below 50 nM, whereas PDGF-induced tyrosine phosphorylation was not affected by concentrations up to 10 microM, thus indicating high selectivity for the inhibition of the ligand-activated EGF-R signal transduction pathway. Compounds 15 and 19 inhibited proliferation of the EGF-dependent MK cell line with IC50 values below 0.5 microM. In addition, two compounds, 9 and 11, showing satisfactory oral bioavailability in mice after oral administration, exhibited good in vivo efficacy at doses of 12.5 and 50 mg/kg in a nude mouse tumor model using xenografts of the EGF-R overexpressing A431 cell line. From SAR studies, a binding mode for 4-(phenylamino)-1H-pyrazolo[3,4-d]pyrimidines, especially for compound 15, at the ATP-binding site of the EGF-R tyrosine kinase is proposed. 4-(Phenylamino)-1H-pyrazolo[3,4-d]pyrimidines represent a new class of highly potent tyrosine kinase inhibitors which preferentially inhibit the EGF-mediated signal transduction pathway and have the potential for further evaluation as anticancer agents.
